Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate
- PMID: 3976757
- DOI: 10.1016/0002-9378(85)90141-3
Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate
Abstract
Eighty pregnant women at high risk of giving birth prematurely were divided randomly into two groups. Treatment with either 17 alpha-hydroxyprogesterone caproate, 250 mg by intramuscular injection once a week, or a placebo was given in a double-blind fashion. Imminent premature labor occurred in 29.0% of the treated group and in 59.4% of the control group (p less than 0.025). The rate of premature deliveries was also significantly lower in the treated group (16.1%) than in the control group (37.82%) (p less than 0.05). There were no cases of perinatal death or fetal malformations in either group. The mean birth weight of all infants of the treated group was significantly higher than in those of the control group (3111.9 +/- 905 gm versus 2680 +/- 813.4 gm, p less than 0.05). The results support treatment with progesterone caproate for the prevention of premature labor.
Similar articles
-
The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population.Am J Obstet Gynecol. 1983 May 15;146(2):187-90. doi: 10.1016/0002-9378(83)91051-7. Am J Obstet Gynecol. 1983. PMID: 6682631 Clinical Trial.
-
Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor.N Engl J Med. 1975 Oct 2;293(14):675-80. doi: 10.1056/NEJM197510022931401. N Engl J Med. 1975. PMID: 1099445 Clinical Trial.
-
Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.N Engl J Med. 2003 Jun 12;348(24):2379-85. doi: 10.1056/NEJMoa035140. N Engl J Med. 2003. PMID: 12802023 Clinical Trial.
-
Recurrent hope for the treatment of preterm delivery.Expert Opin Pharmacother. 2003 Dec;4(12):2363-6. doi: 10.1517/14656566.4.12.2363. Expert Opin Pharmacother. 2003. PMID: 14640934 Review.
-
Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery.Minerva Ginecol. 2009 Oct;61(5):401-9. Minerva Ginecol. 2009. PMID: 19749671 Review.
Cited by
-
17-Alpha-Hydroxyprogesterone vs. Placebo for Preventing of Recurrent Preterm Birth: A Systematic Review and Meta-Analysis of Randomized Trials.Front Med (Lausanne). 2021 Dec 1;8:764855. doi: 10.3389/fmed.2021.764855. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34926508 Free PMC article.
-
Progestin therapy to prevent preterm birth: History and effectiveness of current strategies and development of novel approaches.Placenta. 2019 Apr;79:46-52. doi: 10.1016/j.placenta.2019.01.018. Epub 2019 Jan 28. Placenta. 2019. PMID: 30745115 Free PMC article. Review.
-
Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.Am J Obstet Gynecol. 2014 Feb;210(2):128.e1-6. doi: 10.1016/j.ajog.2013.10.008. Epub 2013 Oct 7. Am J Obstet Gynecol. 2014. PMID: 24113254 Free PMC article. Clinical Trial.
-
Progesterone, cerclage, pessary, or acetylsalicylic acid for prevention of preterm birth in singleton and multifetal pregnancies - A systematic review and meta-analyses.Front Med (Lausanne). 2023 Feb 28;10:1111315. doi: 10.3389/fmed.2023.1111315. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36936217 Free PMC article. Review.
-
Progestogen therapy in threatened miscarriage and unexplained recurrent pregnancy loss: Recommendations by the Thai interest group.J Obstet Gynaecol Res. 2025 Aug;51(8):e70038. doi: 10.1111/jog.70038. J Obstet Gynaecol Res. 2025. PMID: 40797287 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
